Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin.
Iwata
H
H
Biomedical Research Center, Osaka University Medical School, Japan.
Nagano
T
T
Toyo-oka
K
K
Hirose
H
H
Hamaoka
T
T
Fujiwara
H
H
D000818:Animals; D002478:Cells, Cultured; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D017710:Lymphocyte Transfusion; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D011090:Polyenes / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D020123:Sirolimus; D016038:Skin Transplantation / Q000276:immunology*; D013154:Spleen / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016559:Tacrolimus / Q000494:pharmacology*; D014184:Transplantation, Homologous / Q000276:immunology
D007166:Immunosuppressive Agents; D007376:Interleukin-2; D011090:Polyenes; D011994:Recombinant Proteins; D020123:Sirolimus; D016559:Tacrolimus